| Date |
Amount |
Grant Recipient |
Grant Title |
| 05/95 |
$30,000 |
University of Miami |
Treatment of Scabies with Ivermectin |
| 09/95 |
$29,759 |
Oregon Health Sciences University |
Combined Modality Approaches to Treat Retroviral Disease |
| 11/95 |
$15,510 |
Mercy Hospital, Miami |
Clinical Trial of Thalidomide in the Treatment of HIV-Associated KS |
| 06/96 |
$8,560 |
Mercy Hospital, Miami |
Clinical Trial of Cats Claw in Asymptomatic HIV+ Subjects |
| 07/96 |
$27,500 |
Oregon Health Sciences University |
Extension of 1995 Grant (see above) |
| 10/96 |
$24,000 |
University of Miami |
Efficacy of Pentoxifylline in the Treatment of Pruritic Papular Eruption of HIV+ Patients |
| 02/97 |
$40,645 |
University of Kentucky |
Effect of Folinic Acid on the Hematological Toxicity of Selected Medications Used in the Treatment of Chronic HIV |
| 07/97 |
$78,969 |
University of Miami |
Evaluation of CD8 Immunologic Recovery After Subcutaneous IL2 Administration |
| 07/97 |
$45,000 |
Community Research Initiative, New England |
CD-4 Levels That Have Risen as a Result of Initiation of Protease Inhibitor Therapy |
| 07/97 |
$50,500 |
Community Research Initiative, Miami |
Joint Study with CRI New England |
| 08/97 |
$44,900 |
Montrose Clinic, Houston |
Clinical Director for HIV Research Staff Position |
| 08/97 |
$26,000 |
AIDS Project of the Ozarks |
Provide Clinical Trial Access to HIV+ Patients in SW Missouri |
| 10/97 |
$114,615 |
University of Southern California |
Immune Responses to HIV in Humans Infected with a Novel Virus |
| 12/97 |
$39,772 |
City of Hope, CA |
Anti-HIV Activity in Herbs: A Molecular Characterization |
| 12/97 |
$75,000 |
INSERM, France |
Study of Non-Progressor HIV Patients |
| 03/98 |
$65,093 |
Oregon Health Sciences University |
Preclinical Evaluation of Anti-HIV Lipophilic Prodrugs |
| 03/98 |
$58,270 |
Tampa Bay Research Institute |
Effects of Pinecone Extract (PC6) on the Progression of Murine AIDS |
| 05/98 |
$71,500 |
Pediatric AIDS Foundation |
Pediatric CTL Responses and HIV Disease Progression |
| 06/98 |
$70,590 |
Body Positive, Houston |
Use of Anabolic Steroids, Optimum Nutrition, and Exercise Therapy for HIV+ Adult Male Patients |
| 07/98 |
$65,000 |
CRIA, New York |
Pilot Study of the Effect of Recombinant Human Growth Hormone (Serostim) in the Treatment of Truncal Obesity Associated with HIV |
| 07/98 |
$75,000 |
INSERM, France |
Extension Grant from 1997 (see above) |
| 08/98 |
$100,000 |
The Wistar Institute |
Immune Function and Anti-HIV Resistance Following HAART |
| 08/98 |
$42,287 |
University of Kentucky |
Cloning of HIV-1 Genes in Tissue Culture for Drug Screening & Engineering of Therapeutic Antibodies Against HIV-1 Tat Protein |
| 10/98 |
$8,928 |
University of Southern Cal. |
Extension Grant from 1997 (see above) |
| 11/98 |
$74,439 |
UCLA School of Medicine |
Factors Related to Appointment & Medication Non-Adherence in HIV+ Men and Women |
| 01/99 |
$105,686 |
University of Southern Cal. |
Extension Grant from 1998 (see above) |
| 02/99 |
$69,832 |
The Rockefeller University |
Importance of Dendritic Cells in SIV delta nef Vaccines |
| 02/99 |
$53,381 |
St. Louis University |
Enhancement of Anti-HIV Immunity by Sequential Immunization w/Heterologous Live Virus Vectors |
| 03/99 |
$85,121 |
Washington University |
Characterizing Diabetes & Lipid Disorders in HIV+ People Treated with Protease Inhibitors |
| 04/99 |
$60,500 |
Rush-Presbyterian-St. Luke's Med. Center |
Mechanism(s) of Protection Against in utero HIV Transmission |
| 04/99 |
$50,000 |
Robert Wood Johnson Medical School |
Development of a Tat-Antagonist Therapeutic for AIDS |
| 06/99 |
$74,970 |
Mass. General Hospital |
Artificial Thymus for HIV-Induced Immunodeficiency |
| 09/99 |
$30,000 |
Tampa Bay Research Inst. |
Extension Grant from 1998 (see above) |
| 09/99 |
$41,363 |
City of Hope, CA |
Extension Grant from 1997 (see above) |
| 10/99 |
$38,500 |
Columbia University |
Silencing Harmful Genes to Prevent Disease |
| 02/00 |
$25,000 |
The Wistar Institute |
Extension Grant from 1998 (see above) |
| 04/00 |
$47,850 |
University of Kentucky |
Analysis of Antiviral Efficacy of RRI |
| 04/00 |
$64,990 |
UCLA School of Medicine |
Phase I Gene Therapy Study Using a Lentiviral Vector for Patients w/Multi-Drug Resistance to HIV |
| 06/00 |
$91,707 |
Washington University |
Characterizing Osteopenia in HIV+ People Treated w/ Protease Inhibitors |
| 06/00 |
$55,000 |
Robert Wood Johnson Medical School |
Extension Grant from 1999 (see above) |
| 06/00 |
$63,000 |
UCLA School of Dentistry |
Role of Candida Species in Endodontic Infections in HIV+/AIDS Population & Its Effect on Endo. Treatment |
| 10/00 |
$26,675 |
University Hospitals of Cleveland |
Pilot Trial to Evaluate Effect of Antioxidants in HIV+ Patients w/Lipodystrophy or Hyperlactatemia |
| 11/00 |
$45,000 |
State University of New York |
Generation of Anti-HIV Cytotoxic T-Lymphocytes Using Lentivirus Vectors... |
| 03/01 |
$72,050 |
Cornell University |
Role of CCR-5 in Interlukin-12 Production in HIV-1 Infection |
| 04/01 |
$79,200 |
St. Luke's-Roosevelt Hospital Center |
Application of Molecular Techniques to the Study of HIV-Associated Lipodystrophy |
| 05/01 |
$58,267 |
Georgetown University |
Development of HHV-6 U94 As a Novel Anti-HIV Therapy |
| 07/01 |
$87,467 |
Washington Univ. School of Medicine |
Rosiglitazone & Exercise Training: Effects on HIV+ People w/Insulin Resistance, Hypertriglyceridemia, & Adipose Tissue Maldistribution |
| 09/01 |
$77,000 |
Univ. of California, San Diego |
Lentiviral Vectors Interfering w/CD4 Downmodulation as an HIV Anti-viral Strategy |
| 09/01 |
$55,000 |
Univ. of California, San Francisco |
Systemic Delivery of Tat and the Effects on HIV Replication and the Host |
| 10/01 |
$10,000 |
Childrens Hope Foundation |
Emergency Grant (9/11 Impact) |
| 11/01 |
$50,000 |
Aaron Diamond AIDS Research Center |
Aggressive Antiviral Therapy During Acute HIV-1 Infection |
| 11/01 |
$50,072 |
Schneider Childrens Hospital |
Siberian Ginseng: A Modulator of TH1-Like T-cell Cytokine mRNA & Cytokine Protein Expression in Pediatric HIV Infection |
| 02/02 |
$55,000 |
Univ. of Massachusetts |
Determinants of Non-Progressive HIV-1 Infection in Women & Children |
| 02/02 |
$75,843 |
Center for Blood Research |
Subtype-Specific Regulation of HIV1 Gene Expression |
| 03/02 |
$65,000 |
Rush-Presbyterian-St. Luke's Medical Center |
Impact of IL-7 on HIV Infection of Naive Cells...Potential Role of IL-7 as an Immune Modulator |
| 05/02 |
$96,525 |
CRI, New England |
Maintenance HIV Suppression w/Cyclic Weekly HAART 5/2 Schedule... |
| 08/02 |
$103,202 |
Childrens Hospital Los Angeles |
Bone Size & Bone Mineral Density in HIV+ Children & Adolescents |
| 08/02 |
$83,113 |
Washington University |
Extension Grant from 2001 (see above) |
| 09/02 |
$32,141 |
New Jersey Med. School |
Prevalence of Anal HPV & Anal Dysplasia in HIV Seropositive Adolescent & Young Adult Males... |
| 09/02 |
$79,200 |
Dana-Farber Cancer Inst. |
Viral Determinants & Mechanisms for HIV-1 Neurotropism & CNS Pathogenesis |
| 01/03 |
$44,000 |
Ohio State University |
Impact of Anti-AIDS Drugs & Drug Resistance on HIV Evolution |
| 01/03 |
$79,200 |
Mass. General Hospital |
HIV-1/HCV Coinfection: Role of HCV-Specific Tcells in Complicating HIV-1 Infection & Therapy |
| 02/03 |
$71,500 |
Mass. General Hospital |
Comprehensive Assessment of HIV-1 Specific CTL Responses in Infected Chinese for Vaccine Design |
| 03/03 |
$75,000 |
Global Alliance to Immunize Against AIDS (GAIA) |
GAIA AIDS Vaccine Project/Bamako, Mali |
| 04/03 |
$60,000 |
University of Southern California |
HIV Vaccine Development Utilizing a Goat Lentivirus |
| 04/03 |
$25,017 |
The New York Blood Center |
HIV-1 Entry Inhibitors Targeting Hydrophobic Cavity in gp120 |
| 06/03 |
$88,062 |
University of Miami |
Longitudinal Assessment of Autologous Neutralizing Antibodies in Children Perinatally Infected w/HIV-1 |
| 08/03 |
$38,500 |
University of Southern California |
Epidemiology & Clinical Significance of PCP Colonization |
| 09/03 |
$75,000 |
University of California, San Francisco |
Identification of the CD8+ Cell Anti-HIV Factor |
| 02/04 |
$75,000 |
University of Colorado Health Sciences Center |
Alpha-1 Antitrypsin Inhibits HIV-1 |
| 06/04 |
$60,000 |
University of Pittsburgh |
Evaluation of Novel Antiviral Targeting HIV-1 Vpr |
| 06/04 |
$40,000 |
Univ. of California, San Diego |
Protecting Cells from HIV Infection & Destruction In Vivo |
| 08/04 |
$78,650 |
Burnet Institute, Australia |
Role of HIV Infection of Astrocytes in the Development of HIV-Ass'd Dementia |
| 09/04 |
$65,100 |
Johns Hopkins |
Targeting the HIV Macrophage Reservoir |
| 11/04 |
$75,000 |
Aaron Diamond AIDS Research Ctr. |
Inhibition of Integrase-Mediated Viral Nuclear Transport |
| 11/04 |
$80,000 |
Mount Sinai School of Medicine |
Chemical Inhibitors for the HIV Tat/PCAF Complex |
| 04/05 |
$83,981 |
Rush University Medical Center |
Evaluating the Role of Antigen-Specific Tcells in HIV Immunity |
| 04/05 |
$87,718 |
George Washington University |
Mechanisms of Atherogenic Effect of HIV-1 Infection |
| 07/05 |
$11,603 |
Yale University School of Medicine |
CXCR4 Allosteric Agonists |
| 08/05 |
$82,098 |
Wistar Institute |
Mouse Model to Test Efficacy of HIV-1 Vaccines |
| 10/05 |
$110,000 |
UMASS Medical School |
Mechanism of HIV-1 Persistence in the Face of HAART |
| 12/05 |
$160,000 |
CRI, New England |
Randomized Controlled Trial of a Weekly Schedule of Five Days On...Two Days Off... |
| 02/06 |
$104,181 |
Albany Medical College |
Mechanisms of Naturally-Occurring HIV-1 Inhibitors
|
| 04/06 |
$84,018 |
Univ. of Colorado Health Sciences Center |
Alpha-1 Antitrypsin Inhibits HIV-1 (Extension funding) |
| 06/06 |
$97,196 |
Cleveland Clinic |
Analysis of Novel Mutagenic Compounds to Lead HIV to Error Catastrophe |
| 06/06 |
$88,000 |
Univ. of Southern California |
Design of Second Generation HIV-1 Integrase Inhibitors |
| 08/06 |
$90,273 |
Univ. of California, Davis |
Long-term Non-Progressor Resistance Factors |
| 09/06 |
$79,200 |
Thomas Jefferson University |
Role of Heterologous Hep C Virus RNA-Dependent RNA Polymerase in Human Cells...Enhancing RNAi Against HIV-1 |
| 10/06 |
$85,800 |
Medical College of Wisconsin |
HIV Hiding in Mature Dendritic Cells Establish Viral Reservoirs |
| 01/07 |
$65,700 |
University of Minnesota |
Impact of Human APOBEC3 Proteins on HIV Drug Resistance |
| 04/07 |
$80,000 |
University at Buffalo |
Novel Assays for Antiretroviral Intra/Extracellular Measurements |
| 05/07 |
$81,000 |
Roger Williams Medical Center |
Enhancing Potency of Anti-HIV Chimeric Immune Receptors |
| 06/07 |
$79,640 |
Beth Israel Deaconess Med Ctr |
Preclinical Evaluation of Bacterially-Dis-played Anti-HIV Antibodies to Prevent HIV Infection |
| 07/07 |
$65,128 |
UCLA Medical Center |
Assessment of Drug-Resistance Mutation Fitness Costs Across HIV-1 Clades |
| 09/07 |
$88,000 |
Washington University |
HIV PI-Induced Insulin Resistance: Role of SOCS-1 |
| 10/07 |
$59,246 |
Tufts University School of Medicine |
Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV+ Patients |
| 11/07 |
$71,973 |
Univ. of Massachusetts |
Molecular & Biologic Properties of Transmitted HIV-1 Variants in a Mother-Child Cohort |
| 04/08 |
$96,381 |
New York Blood Center |
Developing Cell Penetrating Peptides as HIV-1 Assembly Inhibitors |
| 05/08 |
$33,500 |
Emory University |
Mechanisms of Antiviral Activity of TRIM-5 Alpha Protein |
| 07/08 |
$105,039 |
Population Council |
A Novel DARPins Strategy for Combating HIV |
| 09/08 |
$43,054 |
Imperial College London |
Gene Expression Microarray Analysis of NK Cell Function in the Gastro. Tract of HIV+ People |
| 03/09 |
$40,000 |
Burnet Institute, Australia |
Adaptive Changes in HIV Subtype C Envelope Glycoproteins Contributing to Pathogenicity |
| 06/09 |
$45,047 |
Brigham & Women's Hospital |
Detection of Minority HIV-1 Variants by Deep Sequencing |
| 07/09 |
$35,000 |
Univ. of Minnesota |
Enabling Lethal Restriction of HIV-1 by Human APOBEC3G |
| 10/09 |
$88,000 |
Univ. of California, San Francisco |
Importance of Plasmacytoid Dendritic Cells in HIV Infection |
| 03/10 |
$55,000 |
Washington University, St. Louis |
Dipeptidyl Peptidase-4 Inhibition & Immune Function in HIV |
| 04/10 |
$44,000 |
Univ. of Southern California |
Identification of Novel Cellular Cofactors of HIV |
| 05/10 |
$70,000 |
Univ. of Vermont |
Targeting Human Proteins for Treatment of Cryptosporidosis |
| 07/10 |
$28,435 |
Dartmouth-Hitchcock Medical Center |
Semen Protects Target CD4+ Cells from HIV Infection |
| 09/10 |
$51,953 |
UC Davis |
Flash-Heating Breast Milk to Decrease Morbidity, Improve Growth, & Reduce HIV Transmission in HIV-Exposed Infants |
| 09/10 |
$64,327 |
Rush Univ. Medical Center |
Acupuncture to Reduce HIV-Associated Inflammation |
| 12/10 |
$71,815 |
UC San Diego |
Prosp. Study of Vitamin D on Cutaneous Innate Immune Responses in HIV+ Subjects w/ and w/out CA-MRSA... |
| 05/11 |
$32,919 |
Univ. of Miami |
Host Apolipoprotein E Affects Development of HIV-Ass'd Neurogical Disease |
| 05/11 |
$25,000 |
AIDS Alabama |
Emergency Assistance Grant |
| 07/11 |
$60,000 |
Pennsylvania State University |
Alternative Therapies to Combat HIV: Targeting...Tat by Natural Products |
| 08/11 |
$77,000 |
UC Davis |
Role of the MSS1 Protein in HIV-1/SIV Replication & Pathogenesis |
| 10/11 |
$85,000 |
UCLA |
Telmisartan and Flow-Mediated Dilatation in Older HIV+ Patients at Risk for Cardio Disease |
| 11/11 |
$20,000 |
UCLA |
Assessing Cardio Risk & Impact of Hep C Treatment on Cardio Risk Biomarkers... |
| 12/11 |
$50,000 |
AMFAR |
ARCHE Program Grant |
| 01/12 |
$82,500 |
UCSF |
Restriction of HIV Replication |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
